SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly)
PFE 24.31-0.9%3:59 PM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: John McCarthy12/12/2005 8:39:59 AM
   of 1722
 
12:15AM Investigational target therapy from Eli Lilly may offer progress for Non-Hodgkin's Lymphoma patients (LLY) 53.41 :Data presented offers evidence that an investigational targeted therapy may be useful in treating patients with the most common form of non-Hodgkin's lymphoma (NHL). Phase II data presented at the American Society of Hematology, showed enzastaurin HCl, an investigational compound from Lilly Oncology, slowed the progression of DLBCL in several patients pretreated with chemotherapy. In addition, preclinical data indicate that enzastaurin may have additional effects on cutting off the tumor's blood supply (anti- angiogenesis), increasing the natural death of tumor cells (apoptosis) and reducing the cell's ability to reproduce (cell proliferation). The Phase II multicenter clinical trial evaluated 55 DLBCL patients previously treated with a median of two other therapies, but like many patients with this aggressive cancer, they experienced relapses. Data, presented at ASH by Michael J. Robertson, showed 22% (12 of 55) of study participants treated with enzastaurin were free of disease progression for two months. A quarter of those patients remained progression free with continued responses of 1.5 years to more than three years in duration. Overall, enzastaurin was well tolerated in this patient population and clinical results show that patients treated with enzastaurin experienced minimal side effects.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News